Keep The Hunger On: Analyst Says Soleno Therapeutics' Upside Potential Much Higher Than Downside Risk
Portfolio Pulse from Vandana Singh
Cantor Fitzgerald has initiated coverage on Soleno Therapeutics Inc with an Overweight rating and a price target of $19. Soleno's lead program, DCCR, is in Phase 3 development for Prader-Willi Syndrome (PWS), and the analyst expects positive findings in 3Q23. Despite disappointing Phase 3 trial data three years ago, the analyst sees the upside potential as much higher than any downside risk due to the unmet need in the PWS market.
July 11, 2023 | 7:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has initiated coverage on Soleno Therapeutics with an Overweight rating and a price target of $19. The analyst sees high upside potential for the stock due to the unmet need in the PWS market.
The analyst from Cantor Fitzgerald has given an Overweight rating to Soleno Therapeutics and set a price target of $19, indicating a bullish outlook for the stock. Despite disappointing Phase 3 trial data three years ago, the analyst sees the upside potential as much higher than any downside risk due to the unmet need in the PWS market. This positive outlook could potentially drive the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100